Regarding RHGP, revenue growth IS my concern, but the company is making good money. I have studied this company because this is a value stock with low getting-in price based on Graham theory. 1. The company did not invest in any advertisement like it did in the last year, which is the most important driving force to the pharmaceutical companies in China. The company should do so next year. 2. The company had big account receivable in second quarter, but got most of them back in third quarter with nice amount of cash sitting in the bank account. To Chinese companies, A/C is the most concern to me. 3. Money is money. With 8 million USD net profit for the first 9 months, even zero profit made in the fourth quarter, the stock is still cheap. In my humble opinion, the reason for the stock trading cheap, is because 1). floating is too small; 2). no support from institution... Anyway, JMHO....
The problem with Chinese stocks is that when you buy them an hour later you feel like buying them again.